Idiopathic Pulmonary Fibrosis (original) (raw)

• Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345(7): 517–25
  Article PubMed CAS Google Scholar
• Scadding JG, Hinson KFW. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs): correlation with histology of biopsy with prognosis. Thorax 1967; 22: 291–304
  Article PubMed CAS Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000; 161: 646–64
  Google Scholar
• Anonymous. Interstitial pneumonitis and fibrosis. In: Fraser RS, Müller NL, Coleman N, et al., editors. Fraser and Paré’s diagnosis of diseases of the chest. 4th ed. Philadelphia (PA): WB Saunders, 1999: 1585–623
  Google Scholar
• King TE, Cherniack RM, Schwartz MI. Idiopathic pulmonary fibrosis and other interstitial lung diseases of unknown aetiology. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine. 2nd ed. Philadelphia (PA): WB Saunders, 1994: 1827–49
  Google Scholar
• Katzenstein AA, Myers JL. State of the art. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301–15
  PubMed CAS Google Scholar
• Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995; 50: 1234–9
  Article PubMed CAS Google Scholar
• Egan JJ, Woodcock AA, Stewart JP. Viruses and idiopathic pulmonary fibrosis. Eur Respir J 1997; 10: 1433–7
  Article PubMed CAS Google Scholar
• Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347: 284–9
  Article PubMed CAS Google Scholar
• Hubbard R, Venn A, Smith C, et al. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998; 157: 743–7
  PubMed CAS Google Scholar
• Crystal RG, Gadek JE, Ferrans VJ, et al. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med 1981; 70(3): 542–68
  Article PubMed CAS Google Scholar
• Wollf G, Crystal RG. Biology of pulmonary fibrosis. In: Crystal RG, West JB, Wiebel ER, et al., editors. The lung: scientific foundations. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1997: 2509–24
  Google Scholar
• Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 977–2
  Google Scholar
• Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450–4
  PubMed CAS Google Scholar
• Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113(2): 396–400
  Article PubMed CAS Google Scholar
• Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis in population based and hospital based cohorts. Thorax 1998; 53: 469–76
  Article PubMed CAS Google Scholar
• Bjoraker JA, Ryu JH, Edwin MK. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199–203
  PubMed CAS Google Scholar
• Nicholson AG, Colby TV, Du Bois RM, et al. The prognostic significance of the histological pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213–7
  PubMed CAS Google Scholar
• Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298(15): 801–9
  Article PubMed CAS Google Scholar
• Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histological pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899–905
  PubMed CAS Google Scholar
• Snell GI, Walters EH, Kotsimbos TC, et al. Idiopathic pulmonary fibrosis: in need of focused and systematic management. Med J Aust 2001; 174: 137–40
  PubMed CAS Google Scholar
• Corrin B. Histopathologic patterns in diffuse infiltrative lung disease [seminar]. Proceedings of the European Respiratory Society postgraduate course: diffuse infiltrative lung disease pathology for the pulmonologist; 1998 Sep 19; Geneva
• Nicholson AG, Colby TV, Du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213–7
  PubMed CAS Google Scholar
• Nicholson AG, Wells AU. Nonspecific interstitial pneumonias-nobody said it’s perfect. Am J Respir Crit Care Med 2001; 164: 1553–4
  PubMed CAS Google Scholar
• Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164: 1722–7
  PubMed CAS Google Scholar
• Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164: 193–6
  PubMed CAS Google Scholar
• Katzenstein AA, Myers JL. Idiopathic pulmonary fibrosis: to biopsy or not to biopsy. Am J Respir Crit Care Med 2001; 164: 185–9
  PubMed CAS Google Scholar
• Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung diseases. A prospective study. Chest 1999; 116(5): 1168–74
  Article PubMed CAS Google Scholar
• Chan-Yeung M, Muller NL. Cryptogenic fibrosing alveolitis. Lancet 1997; 350: 651–6
  Article PubMed CAS Google Scholar
• Turner-Warwick M, Burrows B, Johnston A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171–80
  Article PubMed CAS Google Scholar
• Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998; 73: 1085–101
  Article PubMed CAS Google Scholar
• Raghu G. Idiopathic pulmonary fibrosis. A need for treatment with drugs other than corticosteroids -a role for antifibrotic agents? Mayo Clin Proc 1997; 72: 285–7
  Article PubMed CAS Google Scholar
• Goldstein RH, Fine A. Potential therapeutic initiatives for fibrogenic lung diseases. Chest 1995; 108(3): 848–55
  Article PubMed CAS Google Scholar
• Coker RK, Laurent GJ. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax 1997; 52: 294–6
  Article PubMed CAS Google Scholar
• Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998; 11: 1218–21
  Article PubMed CAS Google Scholar
• Nicod LP. Pirfenidone in idiopathic pulmonary fibrosis. Lancet 1999; 354: 268–9
  Article PubMed CAS Google Scholar
• Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79: 1665–73
  Article PubMed CAS Google Scholar
• Egan JJ, Woodcock AA. Does the treatment of cryptogenic fibrosing alveolitis influence prognosis? Respir Med 1996; 90: 127–30
  Article PubMed CAS Google Scholar
• Johnston IDA, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38–44
  Article PubMed CAS Google Scholar
• Parios RJ, King TE. Idiopathic pulmonary fibrosis. In: Lynch III JP, DeRemee RA, editors. Immunologically mediated pulmonary disease. Philadelphia (PA): Lippincott, 1991
  Google Scholar
• Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996; 110(4): 1058–67
  Article PubMed CAS Google Scholar
• Richeldi L, Ferrara G, Davies HR, et al. Corticosteroids for idiopathic pulmonary fibrosis: a systematic review. The Cochrane Collaboration: issue 3. Oxford: Update Software, 2001
  Google Scholar
• Gulsvik A, Kjelsberg F, Bergmann A, et al. High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study. Respiration 1986; 50(4): 252–7
  Article PubMed CAS Google Scholar
• Keogh BA, Bernardo J, Hunninghake GW, et al. Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1983; 127(1): 18–22
  CAS Google Scholar
• Chang, J Raghu G. Use of corticosteroids for treatment of interstitial lung disease. Clin Pulm Med 2000; 7(9): 9–14
  Article Google Scholar
• Gay SG, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063–72
  PubMed CAS Google Scholar
• Brown CH, Turner-Warwick M. The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs. Q J Med 1971; 40(158): 289–302
  PubMed CAS Google Scholar
• Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155: 395–420
  PubMed Google Scholar
• Weese WC, Levine BW, Kazemi H. Interstitial lung disease resistant to corticosteroid therapy: report of three cases treated with azathioprine or cyclophosphamide. Chest 1975; 67(1): 57–60
  Article PubMed CAS Google Scholar
• Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis: clinicopathologic correlation in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65: 661–72
  Article PubMed CAS Google Scholar
• Haslam PL, Turton CWG Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35: 328–39
  Article PubMed CAS Google Scholar
• Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1–8
  PubMed CAS Google Scholar
• Moolman JA, Bardin PG, Rossouw DJ, et al. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592–5
  Article PubMed CAS Google Scholar
• Meier-Sydow J, Weiss SM, Buhl R, et al. Idiopathic pulmonary fibrosis: current concepts and challenges in management. Semin Respir Crit Care Med 1994; 15(1): 77–96
  Article Google Scholar
• Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 444–9
  PubMed CAS Google Scholar
• Douglas WW, Ryu JH, Scroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172–8
  PubMed CAS Google Scholar
• DeRemee RA. New approaches to the treatment of pulmonary fibrosis. Eur Respir J 1994; 7: 427–8
  Article PubMed CAS Google Scholar
• Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 915–8
  PubMed CAS Google Scholar
• Entzian P, Zahringer U, Schaak M, et al. Comparative study on effects of pentoxyifylline, prednisolone and colchicine in experimental alveolitis. Int J Immunopharmacol 1998; 20: 723–35
  Article PubMed CAS Google Scholar
• Egan JJ. New treatments for pulmonary fibrosis? Lancet 1999; 354: 1839–40
  Article PubMed CAS Google Scholar
• Varney VA, Parnell H, Salisbury DT. A double blind randomised placebo study of septrin in the treatment of pulmonary fibrosis (interstitial pneumonia) [abstract]. Am J Respir Crit Care Med 2001; 163: A42
  Google Scholar
• Cherniack RM, Crystal RG, Kalica AR. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis 1991; 143: 680–3
  PubMed CAS Google Scholar
• Willsher ML, Wells AU, Lake F, et al. Proposal for randomised placebo controlled multicentre trial in cryptogenic fibrosing alveolitis. Proceedings of Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 1996; Perth, Western Australia
• Britton J. Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis. Thorax 2000; 55Suppl. 1: S37–40
  Article PubMed Google Scholar
• Fulmer J, Elson N, Von Gal E, et al. Treatment of idiopathic pulmonary fibrosis [abstract]. Clin Res 1978; 26: 538A
  Google Scholar
• Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291–6
  Article PubMed CAS Google Scholar
• Winterbauer RH. The treatment of idiopathic pulmonary fibrosis. Chest 1991; 100(1): 233–5
  Article PubMed CAS Google Scholar
• Cegla UH, Kroidl RF, Meier-Sydow J, et al. Therapy of idiopathic fibrosis of the lung. Experiences with three therapeutic principles: corticosteroids in combination with azathioprine, D-penicillamine and para-amino benzoate. Pneumonologie 1975; 152: 75–92
  Article PubMed CAS Google Scholar
• Cegla UH. Behandlung der idiopathisch fibrosierenden Alveolitis. Treatment of idiopathic fibrosing alveolitis: therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy. Schweiz Med Wochenschr 1977; 107: 184–7
  PubMed CAS Google Scholar
• Shishido M, Ichiki H, Yano M, et al. A case of idiopathic pulmonary fibrosis with histology of usual interstitial pneumonia that responded to pulse therapy followed by combined immunosuppression with prednisolone and azathioprine. Jpn J Thorac Dis 1992; 30(12): 2139–45
  CAS Google Scholar
• Meier-Sydow J, Rust M, Kronenberger H, et al. Langzeitbeobachtung von Lungfunktionsparmetern bei idiopathischen Lungfibrosen unter Prednison und Azathioprin oder D-penicillamin. Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or D-penicillamine. Prax Pneumol 1979; 33Suppl. 1: 680–8
  Google Scholar
• Costabel U, Matthys H. Different therapies and factors influencing response to therapy in idiopathic diffuse fibrosing alveolitis. Respiration 1981; 42: 141–9
  Article PubMed CAS Google Scholar
• Meier-Sydow J, Rust M, Kronenberger H, et al. Survival of patients with idiopathic pulmonary fibrosis following treatment with azathioprine, D-penicillamine or prednisone: ten years of follow-up [abstract]. Chest 1990; 98: S18
  Article Google Scholar
• Johnson MA, Kwan S, Snell NJC, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280–8
  Article PubMed CAS Google Scholar
• O’Donnell K, Keogh B, Cantin A, et al. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1987; 136: 288–92
  Article PubMed Google Scholar
• Baughman RP, Lower EE. Use of intermittent intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102(4): 1090–4
  Article PubMed CAS Google Scholar
• Behr J, Adelmann-Grill BC, Krombach F, et al. Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis. Thorax 1993; 48: 736–42
  Article PubMed CAS Google Scholar
• Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103(1): 69–73
  Article PubMed CAS Google Scholar
• Zisman DA, Lynch JP, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117(6): 1619–26
  Article PubMed CAS Google Scholar
• Meuret G, Fueter R, Gloor F. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine and prednisone. Respiration 1978; 36: 228–33
  Article PubMed CAS Google Scholar
• Eliasson O, Cole SR, Degraff A. Adverse effects of cyclophosphamide in idiopathic pulmonary fibrosis. Conn Med 1985; 49(5): 286–9
  PubMed CAS Google Scholar
• Van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 1950–7
  PubMed Google Scholar
• Kolb M, Kirschner J, Riedel W, et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998; 12: 1409–14
  Article PubMed CAS Google Scholar
• Cozzi PJ, Hall JB. Cyclophosphamide in the treatment of pulmonary diseases: survey of use, training, and practitioner knowledge base. Chest 1999; 116(5): 1158–62
  Article Google Scholar
• Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851–6
  PubMed CAS Google Scholar
• Goodman M, Turner-Warwick M. Pilot study of D-penicillamine therapy in corticosteroid failure patients with widespread pulmonary fibrosis [abstract]. Chest 1978; 74(3): 338
  Google Scholar
• Goodman M, Knight RK, Turner-Warwick M. Pilot studies of penicillamine therapy in steroid failure patients in interstitial lung disease. In: Maini RN, Berry H, editors. Modulation of autoimmunity and disease. Prague: Praeger, 1981: 291–300
  Google Scholar
• Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine and prednisone in the treatment of idiopathic pulmonary fibrosis. Chest 1998; 114(2): 507–12
  Article PubMed CAS Google Scholar
• Liebetrau G, Pielesch W, Ganguin HG, et al. Die Therapie der Lungenfibrosen mit D-penizillamin. Therapy of pulmonary fibrosis with D-penicillamine. Z Gesamte Inn Med 1982; 37: 263–6
  PubMed CAS Google Scholar
• Garcia JEL, Rodriguez FM, Lopez AJ, et al. Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Respir Med 1998; 92: 722–8
  Article Google Scholar
• Alton EWFW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83: 277–89
  Article PubMed CAS Google Scholar
• Venuta F, Rendina EA, Ciriaco P, et al. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation. J Heart Lung Transplant 1993; 12: 909–14
  PubMed CAS Google Scholar
• Homolka J, Svobodova L, Slovakova A. Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia [abstract]. Proceedings of the 97th International Meeting, American Thoracic Society; 2001 May 18–23; San Francisco
  Google Scholar
• Fukazawa M, Kawano M, Hisano S, et al. Efficacy of cyclosporin A for idiopathic pulmonary fibrosis. Eur J Pediatr 1990; 149: 441–2
  Article PubMed CAS Google Scholar
• Rennard SI, Bitterman PB, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. Am Rev Respir Dis 1988; 137: 181–5
  Article PubMed CAS Google Scholar
• Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 220–5
  PubMed CAS Google Scholar
• Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101–4
  Article PubMed CAS Google Scholar
• Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72(3): 201–9
  Article PubMed CAS Google Scholar
• Undurraga AP, Meneses MC, Sabbagh EP, et al. Tratamiento de la fibrosis pulmonar idiopatica con colchicina. Treatment of idiopathic pulmonary fibrosis with colchicine. Rev Med Chil 1998; 126: 1345–53
  PubMed CAS Google Scholar
• Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159: 1061–9
  PubMed CAS Google Scholar
• Ziesche R, Kink E, Herold C, et al. Therapy of chronic interstitial lung disease with a combination of interferon-gamma and low dose prednisolone [abstract]. Chest 1996; 110(4): S25
  Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264–9
  Article PubMed CAS Google Scholar
• Du Bois RM. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1302–4
  Article PubMed Google Scholar
• Raghu G, Noble PW, Brown KK, et al. Interferon gamma-1b in idiopathic pulmonary fibrosis: reanalysis of a published study. American Thoracic Society Continuing Education Monograph Series 2000 Sep: 44–51
• Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79: 1665–73
  Article PubMed CAS Google Scholar
• Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370–2
  Article PubMed CAS Google Scholar
• MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995; 50Suppl. 1: S53–8
  Article PubMed Google Scholar
• Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 431–6
  Article PubMed CAS Google Scholar
• Meyer A, Buhl R, Kampf S, et al. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152: 1055–60
  PubMed CAS Google Scholar
• Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997; 156: 1897–901
  PubMed CAS Google Scholar
• National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines. Canberra: NHMRC, 2000 Feb
  Google Scholar